Enanta Pharmaceuticals. has been granted a patent for compounds that inhibit hepatitis B virus (HBV) proteins and disrupt the HBV life cycle. These compounds, along with their pharmaceutical compositions, are intended for treating HBV infections in affected individuals. GlobalData’s report on Enanta Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Enanta Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Enanta Pharmaceuticals's grant share as of July 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
The patent US12054493B2 describes a novel compound represented by a specific chemical formula (Formula I) that includes a phenyl group with various substituents such as fluoro, chloro, bromo, and others. The claims outline the structural components of the compound, including the substituents on the phenyl group (X), a linking group (Y), and a variable group (R). Additionally, the patent covers pharmaceutical compositions that incorporate this compound along with acceptable carriers or excipients, indicating its potential for therapeutic applications.
Furthermore, the patent details a method for treating or preventing hepatitis B virus (HBV) infections by administering a therapeutically effective amount of the described compound. This method may also involve the use of additional therapeutic agents, including HBV polymerase inhibitors and other antiviral agents, which can be co-formulated with the primary compound. Notably, the claims suggest that these additional agents may be administered at reduced doses or frequencies compared to their standalone therapeutic effectiveness, potentially enhancing treatment efficacy and patient compliance.
To know more about GlobalData’s detailed insights on Enanta Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
